Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant

Summary

This phase I trial studies the side effects and best dose of sorafenib tosylate in treating patients with liver cancer who have undergone a liver transplant. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sorafenib after liver transplant may be an effective treatment for liver cancer

Timeline

Start

2009-01

Primary completion

2010-06

Completion

—

Drugs

Indications